Related Experiment Video

Updated: Jul 2, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?

Hans-Christoph Diener1

  • 1Department of Neurology, University of Essen, Hufelandstrasse 55, D-45122 Essen, Germany. h.diener@uni-essen.de

International Journal of Stroke : Official Journal of the International Stroke Society
|August 19, 2008
PubMed

Insights

Antiplatelet drugs reduce stroke risk in TIA and ischemic stroke patients. Aspirin is effective and safe, while other agents offer marginal benefits with increased bleeding risks, necessitating careful patient selection.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Patients with transient ischemic attack (TIA) or ischemic stroke face a significant annual risk of recurrent stroke (5-20%).
  • Antiplatelet therapy is crucial for secondary stroke prevention, particularly in non-cardiac origin cases, reducing stroke risk and major vascular events.

Purpose of the Study:

  • To evaluate the efficacy and safety of various antiplatelet agents for secondary stroke prevention.
  • To compare aspirin with combination therapies and newer agents in reducing recurrent stroke and vascular death.

Main Methods:

  • Systematic review and meta-analysis of clinical trials on antiplatelet therapies for stroke prevention.
  • Comparison of aspirin, aspirin-dipyridamole, clopidogrel, and GP IIb/IIIa antagonists regarding efficacy and bleeding risk.

Main Results:

  • Low-dose aspirin (50-325 mg) is effective and safer than higher doses for stroke prevention.
  • Aspirin plus dipyridamole showed superior stroke prevention compared to aspirin alone, without increased bleeding.
  • Clopidogrel was not superior to aspirin in unselected patients but beneficial in high-risk individuals; combination therapies and GP IIb/IIIa antagonists offered limited additional benefit with higher bleeding risks.

Conclusions:

  • Aspirin remains a cornerstone of antiplatelet therapy for TIA and ischemic stroke.
  • More potent antiplatelet agents offer marginal efficacy gains over aspirin, often accompanied by increased bleeding complications.
  • Careful patient selection is essential to optimize the benefits of antiplatelet therapy and minimize risks.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...